| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bioterrorism | 12 | 2004 | 28 | 2.040 |
Why?
|
| Streptococcal Infections | 10 | 2025 | 39 | 1.760 |
Why?
|
| Bacterial Infections | 11 | 2010 | 56 | 1.350 |
Why?
|
| HIV Infections | 8 | 2016 | 165 | 1.290 |
Why?
|
| Virus Diseases | 5 | 2012 | 39 | 1.120 |
Why?
|
| Pancreatic Neoplasms | 10 | 2025 | 548 | 1.050 |
Why?
|
| Humans | 103 | 2025 | 28995 | 1.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 9 | 2024 | 285 | 1.020 |
Why?
|
| Anti-Bacterial Agents | 13 | 2025 | 537 | 0.960 |
Why?
|
| Streptococcus pyogenes | 9 | 2025 | 32 | 0.850 |
Why?
|
| Urinary Tract Infections | 3 | 2020 | 39 | 0.790 |
Why?
|
| Anti-Retroviral Agents | 4 | 2016 | 16 | 0.720 |
Why?
|
| Immunosuppressive Agents | 2 | 2013 | 150 | 0.700 |
Why?
|
| Drug Resistance, Viral | 4 | 2016 | 5 | 0.680 |
Why?
|
| Cation Transport Proteins | 5 | 2025 | 60 | 0.680 |
Why?
|
| Bacterial Outer Membrane Proteins | 11 | 1994 | 102 | 0.650 |
Why?
|
| Liver Neoplasms | 6 | 2024 | 167 | 0.650 |
Why?
|
| Drug Resistance, Bacterial | 4 | 2025 | 45 | 0.650 |
Why?
|
| HIV-1 | 3 | 2016 | 59 | 0.640 |
Why?
|
| Neoplastic Stem Cells | 7 | 2021 | 141 | 0.620 |
Why?
|
| Carrier Proteins | 11 | 1994 | 256 | 0.610 |
Why?
|
| Antigens, Bacterial | 12 | 1994 | 166 | 0.580 |
Why?
|
| Histoplasmosis | 2 | 2014 | 10 | 0.570 |
Why?
|
| Bacterial Vaccines | 5 | 2010 | 30 | 0.520 |
Why?
|
| Cachexia | 4 | 2022 | 53 | 0.510 |
Why?
|
| Animals | 39 | 2025 | 10713 | 0.510 |
Why?
|
| Carcinoma, Hepatocellular | 6 | 2024 | 133 | 0.500 |
Why?
|
| Candidiasis | 2 | 2012 | 27 | 0.500 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2025 | 146 | 0.490 |
Why?
|
| Femoral Artery | 2 | 2014 | 58 | 0.490 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2025 | 170 | 0.470 |
Why?
|
| Gram-Negative Bacterial Infections | 2 | 2010 | 22 | 0.460 |
Why?
|
| Chagas Disease | 2 | 2022 | 20 | 0.460 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 3 | 2021 | 26 | 0.460 |
Why?
|
| Foreign-Body Migration | 1 | 2015 | 8 | 0.450 |
Why?
|
| Biological Warfare | 3 | 2004 | 6 | 0.450 |
Why?
|
| Vena Cava Filters | 1 | 2015 | 11 | 0.450 |
Why?
|
| Internal Medicine | 3 | 2012 | 30 | 0.440 |
Why?
|
| Chest Pain | 1 | 2015 | 26 | 0.440 |
Why?
|
| Immunotherapy | 3 | 2025 | 163 | 0.440 |
Why?
|
| Pericarditis | 1 | 2015 | 14 | 0.440 |
Why?
|
| Male | 28 | 2025 | 13983 | 0.440 |
Why?
|
| Mice | 25 | 2025 | 4814 | 0.440 |
Why?
|
| Viral Load | 2 | 2016 | 32 | 0.440 |
Why?
|
| Tumor Microenvironment | 6 | 2025 | 195 | 0.430 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2012 | 44 | 0.430 |
Why?
|
| Aorta, Abdominal | 1 | 2014 | 15 | 0.420 |
Why?
|
| MicroRNAs | 4 | 2024 | 302 | 0.420 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2014 | 28 | 0.420 |
Why?
|
| Competency-Based Education | 2 | 2011 | 18 | 0.420 |
Why?
|
| Vascular Grafting | 1 | 2014 | 11 | 0.420 |
Why?
|
| Nocardia | 1 | 2013 | 2 | 0.410 |
Why?
|
| Nocardia Infections | 1 | 2013 | 4 | 0.410 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2013 | 21 | 0.400 |
Why?
|
| Communicable Diseases, Emerging | 2 | 2010 | 7 | 0.390 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2013 | 251 | 0.390 |
Why?
|
| Candida glabrata | 1 | 2012 | 3 | 0.390 |
Why?
|
| Abdominal Abscess | 1 | 2012 | 9 | 0.380 |
Why?
|
| Terrorism | 2 | 2002 | 10 | 0.380 |
Why?
|
| Fever | 3 | 2008 | 31 | 0.370 |
Why?
|
| Bacterial Proteins | 12 | 2007 | 499 | 0.370 |
Why?
|
| Dyspnea | 2 | 2011 | 25 | 0.370 |
Why?
|
| Cell Line, Tumor | 13 | 2025 | 1351 | 0.360 |
Why?
|
| Internship and Residency | 3 | 2012 | 263 | 0.350 |
Why?
|
| Awards and Prizes | 1 | 2011 | 9 | 0.350 |
Why?
|
| Anti-Infective Agents | 3 | 2007 | 78 | 0.350 |
Why?
|
| Shock, Septic | 2 | 2010 | 38 | 0.350 |
Why?
|
| Antibodies, Monoclonal | 1 | 2013 | 336 | 0.350 |
Why?
|
| Signal Transduction | 7 | 2025 | 1469 | 0.350 |
Why?
|
| Brain | 4 | 2008 | 770 | 0.350 |
Why?
|
| Extracellular Vesicles | 2 | 2025 | 54 | 0.350 |
Why?
|
| Listeriosis | 2 | 2008 | 41 | 0.340 |
Why?
|
| Hepatitis C | 3 | 2011 | 42 | 0.340 |
Why?
|
| Inflammation | 5 | 2024 | 668 | 0.340 |
Why?
|
| Hypoxia | 1 | 2011 | 90 | 0.330 |
Why?
|
| Rahnella | 1 | 2010 | 1 | 0.330 |
Why?
|
| Bacteriology | 1 | 2010 | 1 | 0.330 |
Why?
|
| Pulmonary Embolism | 1 | 2011 | 126 | 0.320 |
Why?
|
| Middle Aged | 16 | 2024 | 7428 | 0.320 |
Why?
|
| Societies, Medical | 2 | 2011 | 93 | 0.320 |
Why?
|
| Adult | 15 | 2020 | 8048 | 0.310 |
Why?
|
| STAT3 Transcription Factor | 3 | 2025 | 97 | 0.310 |
Why?
|
| Curriculum | 2 | 2011 | 307 | 0.310 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2010 | 91 | 0.310 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 472 | 0.300 |
Why?
|
| Surgical Wound Infection | 1 | 2010 | 108 | 0.300 |
Why?
|
| Enterobacteriaceae Infections | 2 | 2020 | 15 | 0.300 |
Why?
|
| Alternative Splicing | 2 | 2020 | 48 | 0.300 |
Why?
|
| Cell Proliferation | 8 | 2022 | 825 | 0.290 |
Why?
|
| Aged | 10 | 2024 | 5608 | 0.290 |
Why?
|
| Listeria monocytogenes | 2 | 2008 | 59 | 0.290 |
Why?
|
| Babesiosis | 1 | 2008 | 2 | 0.290 |
Why?
|
| Ehrlichiosis | 1 | 2008 | 5 | 0.290 |
Why?
|
| Epithelial-Mesenchymal Transition | 5 | 2021 | 120 | 0.280 |
Why?
|
| Malaria | 1 | 2008 | 18 | 0.280 |
Why?
|
| Porphyrias | 1 | 2008 | 2 | 0.280 |
Why?
|
| Streptococcus pneumoniae | 2 | 1999 | 29 | 0.280 |
Why?
|
| Confusion | 1 | 2008 | 5 | 0.280 |
Why?
|
| Fluoroquinolones | 1 | 2007 | 15 | 0.270 |
Why?
|
| Biomarkers, Tumor | 4 | 2025 | 415 | 0.270 |
Why?
|
| Rifamycins | 1 | 2007 | 2 | 0.270 |
Why?
|
| Nitrofurantoin | 1 | 2007 | 3 | 0.270 |
Why?
|
| Chloramphenicol | 1 | 2007 | 6 | 0.270 |
Why?
|
| Tinidazole | 1 | 2007 | 3 | 0.270 |
Why?
|
| Hypoglycemia | 1 | 2007 | 34 | 0.270 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2007 | 10 | 0.270 |
Why?
|
| Metronidazole | 1 | 2007 | 16 | 0.260 |
Why?
|
| Streptogramins | 1 | 2007 | 1 | 0.260 |
Why?
|
| Macrolides | 1 | 2007 | 19 | 0.260 |
Why?
|
| Thiazoles | 1 | 2007 | 50 | 0.260 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2015 | 481 | 0.250 |
Why?
|
| Infection Control | 2 | 2003 | 33 | 0.250 |
Why?
|
| Antiviral Agents | 4 | 2016 | 114 | 0.250 |
Why?
|
| Cell Movement | 4 | 2021 | 376 | 0.240 |
Why?
|
| Neoplasms | 2 | 2025 | 879 | 0.240 |
Why?
|
| Liver Cirrhosis | 2 | 2024 | 78 | 0.240 |
Why?
|
| Aneurysm, Infected | 1 | 2005 | 3 | 0.240 |
Why?
|
| Clinical Medicine | 1 | 2005 | 6 | 0.240 |
Why?
|
| United States | 7 | 2022 | 2247 | 0.230 |
Why?
|
| Treatment Failure | 4 | 2016 | 73 | 0.230 |
Why?
|
| Mentors | 1 | 2005 | 39 | 0.230 |
Why?
|
| Salmonella Infections | 1 | 2005 | 18 | 0.230 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2005 | 24 | 0.230 |
Why?
|
| Global Health | 1 | 2025 | 55 | 0.230 |
Why?
|
| Cytomegalovirus Infections | 2 | 2012 | 36 | 0.230 |
Why?
|
| Research | 1 | 2005 | 93 | 0.230 |
Why?
|
| Salmonella typhimurium | 1 | 2005 | 69 | 0.230 |
Why?
|
| Chemokine CCL2 | 1 | 2025 | 47 | 0.220 |
Why?
|
| Microtubules | 2 | 2016 | 90 | 0.220 |
Why?
|
| Zinc | 2 | 2025 | 63 | 0.220 |
Why?
|
| Microglia | 1 | 2025 | 69 | 0.210 |
Why?
|
| Neoplasm Proteins | 1 | 2025 | 123 | 0.210 |
Why?
|
| Lung Diseases, Fungal | 2 | 2007 | 14 | 0.210 |
Why?
|
| Glioblastoma | 1 | 2025 | 109 | 0.210 |
Why?
|
| Biotechnology | 1 | 2003 | 17 | 0.200 |
Why?
|
| Arenaviruses, New World | 1 | 2003 | 1 | 0.200 |
Why?
|
| Variola virus | 1 | 2003 | 1 | 0.200 |
Why?
|
| Viral Vaccines | 1 | 2003 | 14 | 0.200 |
Why?
|
| Integrin alpha3 | 2 | 2021 | 18 | 0.200 |
Why?
|
| Colonic Neoplasms | 2 | 2017 | 122 | 0.200 |
Why?
|
| Lipopolysaccharides | 6 | 2007 | 157 | 0.190 |
Why?
|
| South Africa | 4 | 2016 | 21 | 0.190 |
Why?
|
| Myocardium | 6 | 2007 | 197 | 0.190 |
Why?
|
| Epitopes | 4 | 1993 | 185 | 0.190 |
Why?
|
| Female | 16 | 2025 | 15688 | 0.190 |
Why?
|
| Chemical Warfare | 1 | 2002 | 3 | 0.190 |
Why?
|
| Warfare | 1 | 2002 | 10 | 0.190 |
Why?
|
| Hepacivirus | 2 | 2013 | 49 | 0.190 |
Why?
|
| Acetate-CoA Ligase | 1 | 2022 | 9 | 0.190 |
Why?
|
| Trypanosoma cruzi | 1 | 2022 | 20 | 0.180 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2022 | 39 | 0.180 |
Why?
|
| Hepatocytes | 2 | 2020 | 88 | 0.180 |
Why?
|
| Antibodies, Bacterial | 6 | 1994 | 103 | 0.180 |
Why?
|
| Brain Neoplasms | 1 | 2025 | 313 | 0.180 |
Why?
|
| Transforming Growth Factor beta | 1 | 2022 | 79 | 0.170 |
Why?
|
| Public Health | 1 | 2002 | 97 | 0.170 |
Why?
|
| Oklahoma | 5 | 2022 | 1058 | 0.170 |
Why?
|
| Cell Plasticity | 1 | 2021 | 10 | 0.170 |
Why?
|
| Osteonecrosis | 1 | 2000 | 8 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2022 | 157 | 0.170 |
Why?
|
| Rheumatic Fever | 3 | 1996 | 6 | 0.170 |
Why?
|
| Disease Models, Animal | 6 | 2018 | 1511 | 0.170 |
Why?
|
| Cell Survival | 3 | 2017 | 419 | 0.170 |
Why?
|
| Tuberculosis, Osteoarticular | 1 | 2000 | 2 | 0.160 |
Why?
|
| Sternum | 1 | 2000 | 7 | 0.160 |
Why?
|
| Gastrointestinal Diseases | 1 | 2020 | 55 | 0.160 |
Why?
|
| Osteomyelitis | 1 | 2000 | 14 | 0.160 |
Why?
|
| beta Catenin | 1 | 2020 | 66 | 0.160 |
Why?
|
| Aortitis | 1 | 1999 | 3 | 0.160 |
Why?
|
| Integrin beta1 | 1 | 2019 | 15 | 0.160 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2000 | 33 | 0.160 |
Why?
|
| Adenocarcinoma | 2 | 2019 | 300 | 0.150 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2021 | 163 | 0.150 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2019 | 48 | 0.150 |
Why?
|
| Isoniazid | 1 | 1999 | 2 | 0.150 |
Why?
|
| Deoxycytidine | 1 | 2019 | 67 | 0.150 |
Why?
|
| Mice, Nude | 5 | 2019 | 332 | 0.150 |
Why?
|
| Antitubercular Agents | 1 | 1999 | 16 | 0.150 |
Why?
|
| Smallpox | 3 | 2003 | 7 | 0.150 |
Why?
|
| Monocytes | 4 | 2008 | 135 | 0.150 |
Why?
|
| Aspergillosis | 1 | 1998 | 11 | 0.150 |
Why?
|
| Needlestick Injuries | 1 | 1998 | 3 | 0.140 |
Why?
|
| Obesity | 1 | 2004 | 702 | 0.140 |
Why?
|
| Citrobacter freundii | 1 | 1998 | 2 | 0.140 |
Why?
|
| Empyema, Pleural | 1 | 1998 | 3 | 0.140 |
Why?
|
| Eikenella corrodens | 1 | 1998 | 2 | 0.140 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2018 | 40 | 0.140 |
Why?
|
| Immunoblastic Lymphadenopathy | 1 | 1998 | 2 | 0.140 |
Why?
|
| Radiography | 2 | 2011 | 203 | 0.140 |
Why?
|
| Abdomen, Acute | 1 | 1998 | 2 | 0.140 |
Why?
|
| Claudin-1 | 1 | 2018 | 7 | 0.140 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2018 | 17 | 0.140 |
Why?
|
| Acute Disease | 4 | 2008 | 156 | 0.140 |
Why?
|
| Kidney Transplantation | 1 | 1998 | 44 | 0.140 |
Why?
|
| Anthrax | 3 | 2003 | 92 | 0.140 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 2067 | 0.140 |
Why?
|
| Weight Loss | 3 | 2008 | 83 | 0.130 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2018 | 79 | 0.130 |
Why?
|
| Epithelial Cells | 3 | 2016 | 266 | 0.130 |
Why?
|
| Bacteremia | 1 | 1998 | 81 | 0.130 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2018 | 120 | 0.130 |
Why?
|
| Arthritis, Infectious | 1 | 1997 | 11 | 0.130 |
Why?
|
| Osteoporosis | 2 | 2009 | 63 | 0.130 |
Why?
|
| Transcription Factors | 1 | 2021 | 523 | 0.130 |
Why?
|
| Kidney Neoplasms | 1 | 2018 | 103 | 0.130 |
Why?
|
| Cell Self Renewal | 1 | 2017 | 8 | 0.130 |
Why?
|
| Penicillin Resistance | 1 | 1996 | 2 | 0.130 |
Why?
|
| beta-Lactams | 2 | 2007 | 4 | 0.130 |
Why?
|
| Cephalosporin Resistance | 1 | 1996 | 3 | 0.130 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 16 | 0.130 |
Why?
|
| Teichoic Acids | 2 | 1994 | 18 | 0.130 |
Why?
|
| Fungemia | 1 | 1996 | 5 | 0.130 |
Why?
|
| HIV Protease Inhibitors | 1 | 2016 | 14 | 0.130 |
Why?
|
| Endocarditis, Bacterial | 1 | 1996 | 15 | 0.130 |
Why?
|
| Cross Reactions | 8 | 2006 | 74 | 0.120 |
Why?
|
| Radiation Injuries | 1 | 2016 | 52 | 0.120 |
Why?
|
| Sensitivity and Specificity | 2 | 2018 | 524 | 0.120 |
Why?
|
| Endocarditis | 1 | 1996 | 20 | 0.120 |
Why?
|
| Hepatitis C, Chronic | 1 | 2016 | 32 | 0.120 |
Why?
|
| Spheroids, Cellular | 3 | 2021 | 53 | 0.120 |
Why?
|
| Mutagenesis, Insertional | 2 | 1994 | 39 | 0.120 |
Why?
|
| Intestines | 1 | 2016 | 118 | 0.120 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2016 | 41 | 0.120 |
Why?
|
| Pharynx | 2 | 1994 | 15 | 0.120 |
Why?
|
| Disease Outbreaks | 1 | 1996 | 54 | 0.120 |
Why?
|
| Diagnosis, Differential | 2 | 2008 | 379 | 0.120 |
Why?
|
| DNA Damage | 1 | 2016 | 152 | 0.120 |
Why?
|
| Stilbenes | 1 | 2016 | 91 | 0.120 |
Why?
|
| Intestine, Small | 1 | 2015 | 66 | 0.120 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2013 | 149 | 0.110 |
Why?
|
| Chromosome Deletion | 1 | 1994 | 16 | 0.110 |
Why?
|
| Penicillins | 3 | 2006 | 12 | 0.110 |
Why?
|
| Equipment Failure | 1 | 2015 | 31 | 0.110 |
Why?
|
| Chromosomes, Bacterial | 1 | 1994 | 21 | 0.110 |
Why?
|
| Anti-HIV Agents | 2 | 2007 | 20 | 0.110 |
Why?
|
| Histoplasma | 1 | 2014 | 6 | 0.110 |
Why?
|
| Mutation Rate | 1 | 2014 | 6 | 0.110 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2014 | 5 | 0.110 |
Why?
|
| Influenza, Human | 2 | 2007 | 95 | 0.110 |
Why?
|
| Virulence | 3 | 2003 | 154 | 0.110 |
Why?
|
| Vaccines, DNA | 2 | 2003 | 11 | 0.100 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2013 | 22 | 0.100 |
Why?
|
| Gene Expression Profiling | 2 | 2017 | 465 | 0.100 |
Why?
|
| Infliximab | 1 | 2013 | 10 | 0.100 |
Why?
|
| Virus Replication | 1 | 2013 | 66 | 0.100 |
Why?
|
| Prognosis | 3 | 2025 | 812 | 0.100 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2014 | 44 | 0.100 |
Why?
|
| Staphylococcus aureus | 4 | 2006 | 121 | 0.100 |
Why?
|
| Plague | 2 | 2003 | 6 | 0.100 |
Why?
|
| Tularemia | 2 | 2003 | 5 | 0.100 |
Why?
|
| Hemorrhagic Fevers, Viral | 2 | 2003 | 2 | 0.100 |
Why?
|
| Educational Measurement | 2 | 2011 | 139 | 0.100 |
Why?
|
| Antifungal Agents | 2 | 2007 | 69 | 0.100 |
Why?
|
| Brucellosis | 2 | 2003 | 6 | 0.100 |
Why?
|
| Hantavirus Infections | 2 | 2003 | 3 | 0.100 |
Why?
|
| Retroperitoneal Space | 1 | 2012 | 9 | 0.100 |
Why?
|
| Cell Differentiation | 1 | 2015 | 427 | 0.100 |
Why?
|
| Indoles | 1 | 2013 | 111 | 0.100 |
Why?
|
| Adolescent | 5 | 2020 | 3223 | 0.100 |
Why?
|
| International Normalized Ratio | 1 | 2012 | 27 | 0.100 |
Why?
|
| Disease Progression | 3 | 2025 | 479 | 0.090 |
Why?
|
| Point-of-Care Systems | 1 | 2012 | 22 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2018 | 275 | 0.090 |
Why?
|
| Drainage | 1 | 2012 | 45 | 0.090 |
Why?
|
| Streptococcus | 2 | 1992 | 17 | 0.090 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2012 | 3 | 0.090 |
Why?
|
| Hepatitis B | 1 | 2012 | 14 | 0.090 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 249 | 0.090 |
Why?
|
| Carcinogenesis | 2 | 2024 | 81 | 0.090 |
Why?
|
| Herpes Zoster | 1 | 2012 | 20 | 0.090 |
Why?
|
| Herpes Simplex | 1 | 2012 | 20 | 0.090 |
Why?
|
| Warfarin | 1 | 2012 | 94 | 0.090 |
Why?
|
| Muscles | 2 | 2022 | 73 | 0.090 |
Why?
|
| Cancer Vaccines | 1 | 2012 | 33 | 0.090 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2012 | 28 | 0.090 |
Why?
|
| Risk Factors | 3 | 2009 | 2134 | 0.090 |
Why?
|
| Fibrosis | 2 | 2010 | 143 | 0.090 |
Why?
|
| Bacteria | 3 | 2006 | 286 | 0.090 |
Why?
|
| Tennessee | 1 | 2011 | 27 | 0.090 |
Why?
|
| Quality Improvement | 1 | 2012 | 127 | 0.090 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 2 | 2022 | 42 | 0.090 |
Why?
|
| Immunoenzyme Techniques | 3 | 2015 | 66 | 0.090 |
Why?
|
| Research Personnel | 1 | 2011 | 40 | 0.090 |
Why?
|
| RNA, Viral | 1 | 2011 | 68 | 0.090 |
Why?
|
| Drug Resistance, Microbial | 2 | 2007 | 36 | 0.080 |
Why?
|
| Equipment Contamination | 1 | 2010 | 8 | 0.080 |
Why?
|
| Food Microbiology | 1 | 2010 | 25 | 0.080 |
Why?
|
| Ciprofloxacin | 1 | 2010 | 22 | 0.080 |
Why?
|
| Anticoagulants | 1 | 2012 | 297 | 0.080 |
Why?
|
| Germany | 1 | 2010 | 24 | 0.080 |
Why?
|
| Water Microbiology | 1 | 2010 | 64 | 0.080 |
Why?
|
| History, 19th Century | 1 | 2010 | 37 | 0.080 |
Why?
|
| Papillomavirus Infections | 1 | 2012 | 156 | 0.080 |
Why?
|
| Catheterization, Central Venous | 1 | 2010 | 38 | 0.080 |
Why?
|
| Cephalosporins | 2 | 2006 | 18 | 0.080 |
Why?
|
| Autoantigens | 2 | 1988 | 213 | 0.080 |
Why?
|
| Cells, Cultured | 4 | 2015 | 1022 | 0.080 |
Why?
|
| History, 20th Century | 1 | 2010 | 85 | 0.080 |
Why?
|
| Antineoplastic Agents | 4 | 2018 | 686 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2016 | 329 | 0.080 |
Why?
|
| Anemia, Sickle Cell | 1 | 2010 | 39 | 0.080 |
Why?
|
| Chronic Disease | 3 | 2024 | 274 | 0.080 |
Why?
|
| Neoplasm Metastasis | 2 | 2021 | 164 | 0.080 |
Why?
|
| Bacterial Adhesion | 3 | 1994 | 27 | 0.080 |
Why?
|
| Heterografts | 2 | 2020 | 66 | 0.080 |
Why?
|
| Tuberculosis, Cardiovascular | 1 | 2009 | 1 | 0.070 |
Why?
|
| Axillary Artery | 1 | 2009 | 2 | 0.070 |
Why?
|
| Apoptosis | 3 | 2018 | 780 | 0.070 |
Why?
|
| BCG Vaccine | 1 | 2009 | 14 | 0.070 |
Why?
|
| Polysaccharides, Bacterial | 1 | 1988 | 13 | 0.070 |
Why?
|
| Blood Chemical Analysis | 2 | 2005 | 17 | 0.070 |
Why?
|
| Lung | 1 | 2011 | 384 | 0.070 |
Why?
|
| Antigens, Ly | 1 | 2008 | 9 | 0.070 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2008 | 17 | 0.070 |
Why?
|
| Acidosis, Lactic | 1 | 2008 | 3 | 0.070 |
Why?
|
| Phenobarbital | 1 | 2008 | 4 | 0.070 |
Why?
|
| Diet, Reducing | 1 | 2008 | 10 | 0.070 |
Why?
|
| Phenytoin | 1 | 2008 | 15 | 0.070 |
Why?
|
| Epilepsy, Tonic-Clonic | 1 | 2008 | 5 | 0.070 |
Why?
|
| Spinal Puncture | 1 | 2008 | 11 | 0.070 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2008 | 15 | 0.070 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2008 | 22 | 0.070 |
Why?
|
| Vomiting | 1 | 2008 | 14 | 0.070 |
Why?
|
| Hormone Replacement Therapy | 1 | 2008 | 9 | 0.070 |
Why?
|
| Valproic Acid | 1 | 2008 | 15 | 0.070 |
Why?
|
| Anticonvulsants | 1 | 2008 | 20 | 0.070 |
Why?
|
| Drug Combinations | 1 | 2008 | 51 | 0.070 |
Why?
|
| Fatal Outcome | 1 | 2008 | 67 | 0.070 |
Why?
|
| Headache | 1 | 2008 | 35 | 0.070 |
Why?
|
| Muscle Proteins | 1 | 1988 | 56 | 0.070 |
Why?
|
| Gene Knockdown Techniques | 2 | 2019 | 134 | 0.070 |
Why?
|
| Survival Rate | 2 | 2019 | 433 | 0.070 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2007 | 8 | 0.070 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2007 | 4 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2007 | 554 | 0.070 |
Why?
|
| Central Nervous System Fungal Infections | 1 | 2007 | 2 | 0.070 |
Why?
|
| Herpesviridae Infections | 1 | 2007 | 17 | 0.070 |
Why?
|
| Tetracycline Resistance | 1 | 2007 | 3 | 0.070 |
Why?
|
| Tetracyclines | 1 | 2007 | 3 | 0.070 |
Why?
|
| Tetracycline | 1 | 2007 | 4 | 0.070 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2007 | 13 | 0.070 |
Why?
|
| Nitro Compounds | 1 | 2007 | 10 | 0.070 |
Why?
|
| Glycopeptides | 1 | 2007 | 3 | 0.070 |
Why?
|
| Oxazolidinones | 1 | 2007 | 4 | 0.070 |
Why?
|
| Polymyxins | 1 | 2007 | 2 | 0.070 |
Why?
|
| Quinolones | 1 | 2007 | 22 | 0.060 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2009 | 166 | 0.060 |
Why?
|
| Aminoglycosides | 1 | 2007 | 10 | 0.060 |
Why?
|
| Peptides, Cyclic | 1 | 2007 | 30 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2019 | 585 | 0.060 |
Why?
|
| Amino Acid Sequence | 4 | 1993 | 697 | 0.060 |
Why?
|
| Electroencephalography | 1 | 2008 | 143 | 0.060 |
Why?
|
| Interleukin-1 | 3 | 2001 | 23 | 0.060 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2006 | 29 | 0.060 |
Why?
|
| Nasal Mucosa | 3 | 1994 | 12 | 0.060 |
Why?
|
| Young Adult | 3 | 2020 | 2842 | 0.060 |
Why?
|
| Rabbits | 4 | 1993 | 278 | 0.060 |
Why?
|
| RNA, Messenger | 4 | 2015 | 668 | 0.060 |
Why?
|
| Immunity, Innate | 1 | 2008 | 232 | 0.060 |
Why?
|
| Reverse Transcriptase Inhibitors | 2 | 2007 | 8 | 0.060 |
Why?
|
| Still's Disease, Adult-Onset | 1 | 2005 | 2 | 0.060 |
Why?
|
| Joint Diseases | 1 | 2005 | 13 | 0.060 |
Why?
|
| Muscle Weakness | 1 | 2005 | 16 | 0.060 |
Why?
|
| Tachycardia | 1 | 2005 | 72 | 0.060 |
Why?
|
| Triggering Receptor Expressed on Myeloid Cells-1 | 1 | 2025 | 6 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 2 | 2016 | 378 | 0.060 |
Why?
|
| Coronary Disease | 1 | 2005 | 120 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2016 | 288 | 0.060 |
Why?
|
| Mice, Transgenic | 2 | 2017 | 513 | 0.050 |
Why?
|
| Coronary Vessels | 1 | 2005 | 154 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2025 | 99 | 0.050 |
Why?
|
| RNA, Small Interfering | 2 | 2018 | 198 | 0.050 |
Why?
|
| Molecular Sequence Data | 4 | 1994 | 1056 | 0.050 |
Why?
|
| Smallpox Vaccine | 1 | 2003 | 3 | 0.050 |
Why?
|
| Mastocytosis, Systemic | 1 | 2003 | 2 | 0.050 |
Why?
|
| Ebolavirus | 1 | 2003 | 8 | 0.050 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2003 | 8 | 0.050 |
Why?
|
| Botulism | 1 | 2003 | 2 | 0.050 |
Why?
|
| Liver Diseases | 1 | 2024 | 52 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2007 | 344 | 0.050 |
Why?
|
| Antitoxins | 1 | 2003 | 13 | 0.050 |
Why?
|
| Anthrax Vaccines | 1 | 2003 | 35 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2008 | 843 | 0.050 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2004 | 38 | 0.050 |
Why?
|
| Glanders | 1 | 2003 | 1 | 0.050 |
Why?
|
| Melioidosis | 1 | 2003 | 2 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 133 | 0.050 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2003 | 45 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2007 | 381 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 1 | 2003 | 68 | 0.050 |
Why?
|
| Drug Design | 1 | 2003 | 63 | 0.050 |
Why?
|
| Acinetobacter | 2 | 2001 | 2 | 0.050 |
Why?
|
| Bone Marrow | 1 | 2003 | 83 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2020 | 1660 | 0.050 |
Why?
|
| Flow Cytometry | 2 | 2016 | 292 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2016 | 1004 | 0.050 |
Why?
|
| Chemical Warfare Agents | 1 | 2002 | 4 | 0.050 |
Why?
|
| Viruses | 1 | 2002 | 20 | 0.050 |
Why?
|
| Disaster Planning | 1 | 2002 | 24 | 0.050 |
Why?
|
| Arenaviridae Infections | 1 | 2002 | 2 | 0.050 |
Why?
|
| Q Fever | 1 | 2002 | 2 | 0.050 |
Why?
|
| Paramyxovirinae | 1 | 2002 | 2 | 0.050 |
Why?
|
| Paramyxoviridae Infections | 1 | 2002 | 2 | 0.050 |
Why?
|
| Dynamin II | 1 | 2022 | 13 | 0.050 |
Why?
|
| Tumor Necrosis Factors | 1 | 2022 | 15 | 0.050 |
Why?
|
| Adenosine Monophosphate | 1 | 2022 | 21 | 0.050 |
Why?
|
| Dextrans | 1 | 2022 | 23 | 0.050 |
Why?
|
| Encephalomyelitis, Venezuelan Equine | 1 | 2002 | 3 | 0.050 |
Why?
|
| Syndecan-1 | 1 | 2022 | 13 | 0.050 |
Why?
|
| Insect Vectors | 1 | 2022 | 12 | 0.050 |
Why?
|
| Vancomycin | 2 | 2007 | 59 | 0.050 |
Why?
|
| Bacillus anthracis | 1 | 2003 | 154 | 0.050 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2001 | 72 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 2 | 2011 | 278 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2018 | 465 | 0.050 |
Why?
|
| Mammals | 1 | 2022 | 48 | 0.050 |
Why?
|
| Cyclin D1 | 1 | 2022 | 38 | 0.050 |
Why?
|
| Methylprednisolone | 1 | 2001 | 15 | 0.050 |
Why?
|
| Time Factors | 3 | 2012 | 1619 | 0.040 |
Why?
|
| Vaccination | 1 | 2003 | 213 | 0.040 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2000 | 9 | 0.040 |
Why?
|
| Sialoglycoproteins | 1 | 2000 | 8 | 0.040 |
Why?
|
| North America | 1 | 2020 | 41 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2001 | 128 | 0.040 |
Why?
|
| Gene Expression | 3 | 2014 | 417 | 0.040 |
Why?
|
| Lipids | 1 | 2022 | 220 | 0.040 |
Why?
|
| SOX9 Transcription Factor | 1 | 2020 | 12 | 0.040 |
Why?
|
| alpha-Fetoproteins | 1 | 2020 | 18 | 0.040 |
Why?
|
| Hep G2 Cells | 1 | 2020 | 31 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2021 | 190 | 0.040 |
Why?
|
| Macrophage Activation | 1 | 2020 | 32 | 0.040 |
Why?
|
| Radionuclide Imaging | 1 | 2000 | 56 | 0.040 |
Why?
|
| Bone and Bones | 1 | 2000 | 78 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2016 | 876 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2020 | 119 | 0.040 |
Why?
|
| Equilibrative Nucleoside Transporter 1 | 1 | 2019 | 15 | 0.040 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2019 | 33 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2019 | 58 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2019 | 90 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2011 | 194 | 0.040 |
Why?
|
| Food-Drug Interactions | 1 | 1999 | 3 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2000 | 202 | 0.040 |
Why?
|
| Biological Availability | 1 | 1999 | 44 | 0.040 |
Why?
|
| Bacterial Toxins | 1 | 2002 | 273 | 0.040 |
Why?
|
| Phagocytosis | 2 | 2001 | 81 | 0.040 |
Why?
|
| Child | 2 | 2014 | 2327 | 0.040 |
Why?
|
| Drug Interactions | 1 | 1999 | 79 | 0.040 |
Why?
|
| Itraconazole | 1 | 1998 | 9 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2025 | 2427 | 0.040 |
Why?
|
| Cisplatin | 1 | 2019 | 186 | 0.040 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2018 | 45 | 0.040 |
Why?
|
| Amphotericin B | 1 | 1998 | 19 | 0.040 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 1998 | 1 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 1998 | 31 | 0.040 |
Why?
|
| Random Allocation | 1 | 2018 | 152 | 0.040 |
Why?
|
| Reference Values | 1 | 2018 | 200 | 0.040 |
Why?
|
| Opportunistic Infections | 1 | 1998 | 17 | 0.040 |
Why?
|
| Pancreatectomy | 1 | 2018 | 58 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 194 | 0.030 |
Why?
|
| Saliva | 2 | 1988 | 96 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 1998 | 52 | 0.030 |
Why?
|
| Genes, Bacterial | 2 | 1994 | 110 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2018 | 314 | 0.030 |
Why?
|
| Sacroiliac Joint | 1 | 1997 | 4 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2005 | 612 | 0.030 |
Why?
|
| Genes, APC | 1 | 2017 | 14 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2016 | 515 | 0.030 |
Why?
|
| Monobactams | 2 | 2007 | 6 | 0.030 |
Why?
|
| Receptor, Notch1 | 1 | 2017 | 27 | 0.030 |
Why?
|
| Enterocytes | 1 | 2016 | 15 | 0.030 |
Why?
|
| Carbapenems | 2 | 2007 | 6 | 0.030 |
Why?
|
| Gene Products, pol | 1 | 2016 | 1 | 0.030 |
Why?
|
| Ceftriaxone | 1 | 1996 | 6 | 0.030 |
Why?
|
| Cytokines | 1 | 1999 | 452 | 0.030 |
Why?
|
| Rifampin | 1 | 1996 | 7 | 0.030 |
Why?
|
| pol Gene Products, Human Immunodeficiency Virus | 1 | 2016 | 1 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 480 | 0.030 |
Why?
|
| Bone Density | 2 | 2009 | 101 | 0.030 |
Why?
|
| Cell Membrane Permeability | 1 | 2016 | 44 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2016 | 21 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2017 | 127 | 0.030 |
Why?
|
| Whole-Body Irradiation | 1 | 2016 | 40 | 0.030 |
Why?
|
| Dinoprostone | 1 | 2016 | 42 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2016 | 32 | 0.030 |
Why?
|
| Cyclooxygenase 2 | 1 | 2016 | 68 | 0.030 |
Why?
|
| Integrases | 1 | 2016 | 39 | 0.030 |
Why?
|
| Candida | 1 | 1996 | 23 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2016 | 71 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2018 | 404 | 0.030 |
Why?
|
| Stem Cells | 1 | 2016 | 123 | 0.030 |
Why?
|
| Demography | 1 | 1996 | 94 | 0.030 |
Why?
|
| Developing Countries | 1 | 1996 | 49 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2016 | 163 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2015 | 75 | 0.030 |
Why?
|
| Models, Biological | 1 | 2018 | 469 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 1032 | 0.030 |
Why?
|
| Genotype | 1 | 2016 | 461 | 0.030 |
Why?
|
| Genes, Synthetic | 1 | 1994 | 6 | 0.030 |
Why?
|
| Adhesins, Bacterial | 1 | 1994 | 7 | 0.030 |
Why?
|
| Prevalence | 1 | 2016 | 521 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 1994 | 62 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 1996 | 264 | 0.030 |
Why?
|
| Peptides | 3 | 1992 | 297 | 0.030 |
Why?
|
| Cell Wall | 1 | 1994 | 68 | 0.030 |
Why?
|
| Longevity | 1 | 2015 | 141 | 0.030 |
Why?
|
| Incidence | 1 | 1996 | 573 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2018 | 641 | 0.030 |
Why?
|
| Chorea | 1 | 1993 | 8 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2013 | 32 | 0.030 |
Why?
|
| Transcriptome | 1 | 2015 | 232 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2014 | 284 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2013 | 202 | 0.020 |
Why?
|
| Biomarkers | 1 | 2016 | 782 | 0.020 |
Why?
|
| Rats | 2 | 2007 | 1592 | 0.020 |
Why?
|
| Mutation | 1 | 2017 | 869 | 0.020 |
Why?
|
| Phenotype | 1 | 1994 | 687 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2012 | 76 | 0.020 |
Why?
|
| Immunization, Passive | 1 | 1992 | 20 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2012 | 84 | 0.020 |
Why?
|
| Oncogene Proteins | 1 | 2012 | 23 | 0.020 |
Why?
|
| Age Factors | 1 | 2014 | 740 | 0.020 |
Why?
|
| Replicon | 1 | 2011 | 7 | 0.020 |
Why?
|
| Keratin-19 | 1 | 2011 | 5 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 60 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2014 | 898 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2012 | 57 | 0.020 |
Why?
|
| Synovial Membrane | 1 | 1991 | 13 | 0.020 |
Why?
|
| Structure-Activity Relationship | 2 | 1988 | 209 | 0.020 |
Why?
|
| Cartilage, Articular | 1 | 1991 | 44 | 0.020 |
Why?
|
| U937 Cells | 2 | 2001 | 8 | 0.020 |
Why?
|
| Sarcolemma | 2 | 1988 | 6 | 0.020 |
Why?
|
| Myosins | 2 | 1988 | 7 | 0.020 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1991 | 134 | 0.020 |
Why?
|
| Malnutrition | 1 | 2009 | 31 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2009 | 75 | 0.020 |
Why?
|
| Administration, Intravesical | 1 | 2009 | 16 | 0.020 |
Why?
|
| Vitamin D Deficiency | 1 | 2009 | 31 | 0.020 |
Why?
|
| Interleukin-6 | 2 | 2001 | 198 | 0.020 |
Why?
|
| Lethal Dose 50 | 1 | 1988 | 14 | 0.020 |
Why?
|
| Administration, Intranasal | 1 | 1988 | 13 | 0.020 |
Why?
|
| Iliac Artery | 1 | 2009 | 19 | 0.020 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2009 | 44 | 0.020 |
Why?
|
| Opsonin Proteins | 1 | 1988 | 5 | 0.020 |
Why?
|
| In Vitro Techniques | 2 | 2001 | 242 | 0.020 |
Why?
|
| Liver | 1 | 2011 | 471 | 0.020 |
Why?
|
| Calcium | 1 | 2009 | 243 | 0.020 |
Why?
|
| Central Nervous System | 1 | 2008 | 43 | 0.020 |
Why?
|
| Mass Screening | 1 | 2009 | 159 | 0.020 |
Why?
|
| Drug Implants | 1 | 2007 | 14 | 0.020 |
Why?
|
| Immunoglobulin A | 1 | 1988 | 23 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2007 | 25 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2008 | 109 | 0.020 |
Why?
|
| Arterioles | 1 | 2007 | 61 | 0.020 |
Why?
|
| Protein Conformation | 1 | 1988 | 259 | 0.020 |
Why?
|
| Antiporters | 1 | 2007 | 6 | 0.020 |
Why?
|
| Minocycline | 1 | 2007 | 7 | 0.020 |
Why?
|
| Myocytes, Cardiac | 1 | 2007 | 64 | 0.020 |
Why?
|
| Doxycycline | 1 | 2007 | 19 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2008 | 247 | 0.020 |
Why?
|
| Linezolid | 1 | 2007 | 4 | 0.020 |
Why?
|
| Acetamides | 1 | 2007 | 3 | 0.020 |
Why?
|
| Gram-Positive Bacteria | 1 | 2007 | 33 | 0.020 |
Why?
|
| Daptomycin | 1 | 2007 | 6 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2007 | 138 | 0.020 |
Why?
|
| Respiratory Tract Infections | 1 | 2007 | 37 | 0.020 |
Why?
|
| Legionella pneumophila | 1 | 2006 | 5 | 0.020 |
Why?
|
| Chlamydophila pneumoniae | 1 | 2006 | 4 | 0.020 |
Why?
|
| Staphylococcus epidermidis | 1 | 2006 | 7 | 0.020 |
Why?
|
| Mycoplasma pneumoniae | 1 | 2006 | 11 | 0.020 |
Why?
|
| Desensitization, Immunologic | 1 | 2006 | 2 | 0.020 |
Why?
|
| Skin Tests | 1 | 2006 | 3 | 0.020 |
Why?
|
| beta-Lactam Resistance | 1 | 2006 | 6 | 0.020 |
Why?
|
| Anaphylaxis | 1 | 2006 | 7 | 0.020 |
Why?
|
| Community-Acquired Infections | 1 | 2006 | 31 | 0.020 |
Why?
|
| Molecular Weight | 1 | 1987 | 122 | 0.020 |
Why?
|
| Enterococcus | 1 | 2006 | 19 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2006 | 66 | 0.020 |
Why?
|
| Gram-Negative Bacteria | 1 | 2007 | 62 | 0.020 |
Why?
|
| Drug Hypersensitivity | 1 | 2006 | 23 | 0.020 |
Why?
|
| Cross Infection | 1 | 2006 | 37 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2007 | 245 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1987 | 257 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2007 | 169 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2006 | 191 | 0.020 |
Why?
|
| Tibia | 1 | 2005 | 39 | 0.010 |
Why?
|
| Absorptiometry, Photon | 1 | 2005 | 101 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 225 | 0.010 |
Why?
|
| Biomechanical Phenomena | 1 | 2005 | 182 | 0.010 |
Why?
|
| Bone Marrow Examination | 1 | 2003 | 4 | 0.010 |
Why?
|
| Splenomegaly | 1 | 2003 | 10 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 2003 | 15 | 0.010 |
Why?
|
| Mast Cells | 1 | 2003 | 9 | 0.010 |
Why?
|
| Rectum | 1 | 2003 | 50 | 0.010 |
Why?
|
| Abdominal Pain | 1 | 2003 | 35 | 0.010 |
Why?
|
| Alcoholism | 1 | 2003 | 121 | 0.010 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2000 | 10 | 0.010 |
Why?
|
| Culture Media | 1 | 2000 | 99 | 0.010 |
Why?
|
| Intracellular Fluid | 1 | 1999 | 12 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 1999 | 74 | 0.010 |
Why?
|
| Epithelium | 1 | 1994 | 40 | 0.010 |
Why?
|
| DNA Primers | 1 | 1994 | 147 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1994 | 208 | 0.010 |
Why?
|
| Base Sequence | 1 | 1994 | 589 | 0.010 |
Why?
|
| DNA, Bacterial | 1 | 1994 | 310 | 0.010 |
Why?
|
| Cheek | 1 | 1992 | 10 | 0.010 |
Why?
|
| Mouth Mucosa | 1 | 1992 | 16 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1991 | 114 | 0.010 |
Why?
|
| Autoantibodies | 1 | 1988 | 483 | 0.000 |
Why?
|